The following is a summary of “Factors affecting D90 High-risk Clinical Target Volumes (HR-CTV dose) of intracavitary and ...

Shares of Novocure Ltd. skyrocketed over 55% on Monday afternoon, reaching levels last seen in August 2023, as the company ...

The company’s success with the PANOVA-3 trial is just one of many milestones that demonstrate its potential to make a significant impact in oncology. Novocure’s strong YTD stock performance and ...

The boost in stock value is primarily attributed to the company’s recent announcement of positive final results from a Phase 2 study of its lead oncology drug, CM24. This milestone positions Purple ...

Shares of Purple Biotech ($PPBT) surged more than 45% on Monday morning, reaching their highest levels since early October.

Senti Biosciences shares surge as SENTI-202 trial shows promise in AML patients; company secures $37.6M in private equity ...

Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company advancing innovative protein conjugates for cancer and other life-threatening diseases, today announced the dosing of the ...